Reference
FDA investigating risk of severe hypocalcemia in patients on dialysis receiving osteoporosis medicine Prolia (denosumab) Internet Document : 30 Nov 2022. Available from: URL: https://www.fda.gov/drugs/drug-safety-and-availability/fda-investigating-risk-severe-hypocalcemia-patients-dialysis-receiving-osteoporosis-medicine-prolia
Rights and permissions
About this article
Cite this article
FDA investigating denosumab-related hypocalcaemia in patients on dialysis. Reactions Weekly 1936, 3 (2022). https://doi.org/10.1007/s40278-022-29200-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-022-29200-4